The defender’s contract at Atletico is up at the end of the season Godin is the captain of Uruguay’s national team targets Latest Manchester United transfer newsIt was reported Godin was set to sign a new deal after deciding to stay, however talks have not progressed as planned.It means the 32-year-old is out of contract in the summer and can leave for free at the end of June.Manchester United have been alerted to that situation and remain interested in striking a deal for the centre-back. Top nine Premier League free transfers of the decade Latest Transfer News Man United joined by three other clubs in race for Erling Haaland targets RANKED 2 LATEST Kevin De Bruyne ‘loves Man City and wants to keep winning’, reveals father 2 IN DEMAND Tony Cascarino backs Everton to sign two strikers for Carlo Ancelotti The biggest market value losers in 2019, including Bale and ex-Liverpool star And, according to Corriere dello Sport, Milan are also trying to sign Godin on a free in the summer.The club’s technical director, Leonardo, has already sounded out the defender about a move to Italy and he is reportedly hopeful a deal can be done. AC Milan have joined Manchester United in the race for Atletico Madrid defender Diego Godin.The Old Trafford club tried to sign the Uruguay international last summer, but they failed with an approach on transfer deadline day. LIVING THE DREAM Where every Premier League club needs to strengthen in January moving on Arsenal transfer news LIVE: Ndidi bid, targets named, Ozil is ‘skiving little git’ REVEALED Cavani ‘agrees’ to join new club and will complete free transfer next summer
On Meet the Press yesterday, Anthony Fauci was asked whether it was “hyperbole” that the world would have an Ebola vaccine today if Congress had more generously funded the U.S. National Institutes of Health (NIH). “You can’t say we would or would not have this or that,” said Fauci, who heads NIH’s National Institute of Allergy and Infectious Diseases (NIAID) in Bethesda, Maryland, a leading supporter of Ebola vaccine research.A week earlier, here’s what Fauci’s boss, NIH Director Francis Collins, told The Huffington Post: “Frankly, if we had not gone through our 10-year slide in research support, we probably would have had a vaccine in time for this that would’ve gone through clinical trials and would have been ready.”NIAID’s high-profile director challenging the NIH director is the kind of political contretemps that easily explodes into a great inside-the-Beltway brouhaha. Witness the story in The Washington Post story today, “A public dispute between NIH officials over Ebola,” that references several other related stories.Sign up for our daily newsletterGet more great content like this delivered right to you!Country *AfghanistanAland IslandsAlbaniaAlgeriaAndorraAngolaAnguillaAntarcticaAntigua and BarbudaArgentinaArmeniaArubaAustraliaAustriaAzerbaijanBahamasBahrainBangladeshBarbadosBelarusBelgiumBelizeBeninBermudaBhutanBolivia, Plurinational State ofBonaire, Sint Eustatius and SabaBosnia and HerzegovinaBotswanaBouvet IslandBrazilBritish Indian Ocean TerritoryBrunei DarussalamBulgariaBurkina FasoBurundiCambodiaCameroonCanadaCape VerdeCayman IslandsCentral African RepublicChadChileChinaChristmas IslandCocos (Keeling) IslandsColombiaComorosCongoCongo, The Democratic Republic of theCook IslandsCosta RicaCote D’IvoireCroatiaCubaCuraçaoCyprusCzech RepublicDenmarkDjiboutiDominicaDominican RepublicEcuadorEgyptEl SalvadorEquatorial GuineaEritreaEstoniaEthiopiaFalkland Islands (Malvinas)Faroe IslandsFijiFinlandFranceFrench GuianaFrench PolynesiaFrench Southern TerritoriesGabonGambiaGeorgiaGermanyGhanaGibraltarGreeceGreenlandGrenadaGuadeloupeGuatemalaGuernseyGuineaGuinea-BissauGuyanaHaitiHeard Island and Mcdonald IslandsHoly See (Vatican City State)HondurasHong KongHungaryIcelandIndiaIndonesiaIran, Islamic Republic ofIraqIrelandIsle of ManIsraelItalyJamaicaJapanJerseyJordanKazakhstanKenyaKiribatiKorea, Democratic People’s Republic ofKorea, Republic ofKuwaitKyrgyzstanLao People’s Democratic RepublicLatviaLebanonLesothoLiberiaLibyan Arab JamahiriyaLiechtensteinLithuaniaLuxembourgMacaoMacedonia, The Former Yugoslav Republic ofMadagascarMalawiMalaysiaMaldivesMaliMaltaMartiniqueMauritaniaMauritiusMayotteMexicoMoldova, Republic ofMonacoMongoliaMontenegroMontserratMoroccoMozambiqueMyanmarNamibiaNauruNepalNetherlandsNew CaledoniaNew ZealandNicaraguaNigerNigeriaNiueNorfolk IslandNorwayOmanPakistanPalestinianPanamaPapua New GuineaParaguayPeruPhilippinesPitcairnPolandPortugalQatarReunionRomaniaRussian FederationRWANDASaint Barthélemy Saint Helena, Ascension and Tristan da CunhaSaint Kitts and NevisSaint LuciaSaint Martin (French part)Saint Pierre and MiquelonSaint Vincent and the GrenadinesSamoaSan MarinoSao Tome and PrincipeSaudi ArabiaSenegalSerbiaSeychellesSierra LeoneSingaporeSint Maarten (Dutch part)SlovakiaSloveniaSolomon IslandsSomaliaSouth AfricaSouth Georgia and the South Sandwich IslandsSouth SudanSpainSri LankaSudanSurinameSvalbard and Jan MayenSwazilandSwedenSwitzerlandSyrian Arab RepublicTaiwanTajikistanTanzania, United Republic ofThailandTimor-LesteTogoTokelauTongaTrinidad and TobagoTunisiaTurkeyTurkmenistanTurks and Caicos IslandsTuvaluUgandaUkraineUnited Arab EmiratesUnited KingdomUnited StatesUruguayUzbekistanVanuatuVenezuela, Bolivarian Republic ofVietnamVirgin Islands, BritishWallis and FutunaWestern SaharaYemenZambiaZimbabweI also wish to receive emails from AAAS/Science and Science advertisers, including information on products, services and special offers which may include but are not limited to news, careers information & upcoming events.Required fields are included by an asterisk(*)As it turns out, Fauci and Collins agree that big pharma’s lack of interest in Ebola vaccine development is the main reason no product was ready for this epidemic.In 2000, NIH researchers published the first convincing evidence that an Ebola vaccine—built around an adenovirus “vector” that carried a gene for the Ebola surface protein—could protect monkeys. A review article about the field in 2003, co-authored by leading Ebola vaccine developer Thomas Geisbert now at the University of Texas Medical Branch in Galveston, noted that the “small global market has generated little commercial interest.” But preclinical research into different Ebola vaccines, in part funded by NIAID, continued apace. Five years later, in a study that used the vesicular stomatitis virus (VSV) as the vector for an Ebola gene, Geisbert and co-authors wrote: “Remarkable progress has been made over the last few years in developing candidate preventive vaccines that can protect nonhuman primates.”Geisbert told ScienceInsider he “completely” agrees with Fauci’s assessment. “His comment is spot on,” Geisbert says. “The smaller companies that were working on Ebola vaccines and treatments did not have the financial resources” to make the clinical grade product needed to stage human studies. NIH funding typically supports research, not product development.There were also problems with the strain of adenovirus that served as a backbone of the NIH vaccine in the 2000 experiment—known as Ad5. It was also used in an AIDS vaccine, but in 2013 was clearly linked to increased risk of transmission of HIV. Researchers using Ad5 for other vaccines promptly dropped it; NIH’s current Ebola vaccine now in early human trials uses a chimpanzee adenovirus. If NIH had invested in the scale-up of the Ad5-based Ebola vaccine, the vials may well have ended up in the trash.Geisbert’s VSV approach was funded primarily by the Public Health Agency of Canada, not NIH. That vaccine entered human trials last week. Geisbert is now pursuing yet another VSV vaccine, made by Profectus Biosciences in Tarrytown, New York and Baltimore, Maryland, that he believes has a better safety profile.Collins says he and Fauci agree that if the NIH had not lost “purchasing power” over the past decade, “NIH-funded Ebola research would be further along,” he wrote ScienceInsider in a statement. “[C]onstrained resources have slowed the process in developing an Ebola vaccine,” he wrote. But Collins backpedaled on his earlier comment, echoing Geisbert. “Because of the extremely limited market potential prior to the 2014 outbreak, there was little industrial interest in an Ebola vaccine,” he noted. “So while NIH readiness might well have advanced to a later stage without the budget situation, it would still have been difficult to have hundreds of thousands of doses of a vaccine in vials, ready to administer.”*The Ebola Files: Given the current Ebola outbreak, unprecedented in terms of number of people killed and rapid geographic spread, Science and Science Translational Medicine have made a collection of research and news articles on the viral disease freely available to researchers and the general public.